logo.jpg
PCI Biotech: Exercise of employee share options, mandatory notification of trade and resolution to increase share capital
02 sept. 2020 12h14 HE | PCI Biotech Holding ASA
Oslo (Norway), 2 September 2020 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”). 1.  ...
logo.jpg
PCI Biotech announce a research collaboration with DCprime to explore novel cancer vaccination concepts
01 sept. 2020 03h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 1 September 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation and DCprime, the...
logo.jpg
PCI Biotech: First half-year 2020 results
26 août 2020 01h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 26 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year and Q2 2020 results. Please find enclosed the report...
logo.jpg
PCI Biotech: Invitation to second quarter and first half 2020 results presentation
19 août 2020 03h21 HE | PCI Biotech Holding ASA
Oslo, Norway, 19 August 2020 - PCI Biotech’s (OSE: PCIB) second quarter and first half 2020 interim report will be released on 26 August 2020 at 07.00 CEST. The interim report and presentation will be...
logo.jpg
PCI Biotech: Publication of case report series from the Phase I study in bile duct cancer
19 août 2020 02h22 HE | PCI Biotech Holding ASA
Oslo (Norway), 19 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that a case report series from the Phase I study with PCI Biotech's proprietary...
logo.jpg
PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca
13 juil. 2020 13h31 HE | PCI Biotech Holding ASA
Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research...
logo.jpg
PCI Biotech: Minutes from Annual General Meeting 2020
27 mai 2020 06h04 HE | PCI Biotech Holding ASA
Oslo, 27 May 2020. The Annual General Meeting in PCI Biotech Holding ASA took place today, 27 May 2020. All proposals were resolved by the Annual General Meeting as presented in the notice convening...
logo.jpg
PCI Biotech: Disclosure of voting rights for Chairman of the Board
26 mai 2020 07h20 HE | PCI Biotech Holding ASA
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...
logo.jpg
PCI Biotech: Notice of Annual General Meeting 2020
06 mai 2020 05h00 HE | PCI Biotech Holding ASA
Oslo, Norway 6 May 2020 - The Annual General Meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 27 May 2020 at 10:00am (CEST). Due to...
logo.jpg
PCI Biotech: First quarter 2020 results
06 mai 2020 01h00 HE | PCI Biotech Holding ASA
Oslo (Norway), 6 May 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first quarter 2020 results. Please find enclosed the report and...